AstraZeneca’s Tezspire (tezepelumab) Receives NICE Recommendation as an Add-On Treatment for Severe Uncontrolled Asthma
Shots:
- The NICE has issued final draft guidance recommending Tezspire for use within NHS England and NHS Wales as an add-on maintenance therapy in adult and adolescent patients aged ≥12yrs. with sev. asthma
- The recommendation was based on the (PATHFINDER) program incl. the P-III trial (NAVIGATOR) evaluating tezepelumab vs PBO which demonstrated a 56% reduction in AAER (0.93 vs 2.10). The results were published in the NEJM
- In patients with a blood eosinophil count of <300 cells/ µL, the annualized rate was 1.02 vs 1.73 & improvements in 2EPs over baseline, incl. lung function, asthma control & health-related QoL, were well tolerated and resulted in reductions in asthma exacerbations in (NAVIAGTOR) & (SOURCE) trials with no clinical differences in safety results
Ref: tezspire | Image: tezspire
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
